Hailu Chen Selected Research

diroximel fumarate

1/2022	Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
1/2021	Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study.
11/2020	Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
1/2020	Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hailu Chen Research Topics

Disease

3	Multiple Sclerosis 01/2022 - 01/2020
2	Relapsing-Remitting Multiple Sclerosis 11/2020 - 01/2020
1	Esophageal Squamous Cell Carcinoma 01/2015
1	Neoplasm Metastasis (Metastasis) 01/2015

Drug/Important Bio-Agent (IBA)

4	FumaratesIBA 01/2022 - 01/2020
4	diroximel fumarateIBA 01/2022 - 01/2020
2	Dimethyl FumarateIBA 01/2022 - 01/2020

Therapy/Procedure

1	Therapeutics 01/2015